A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer Interventions: Drug: Alisertib; Drug: Endocrine therapy Sponsors: Puma Biotechnology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Hormones | Research | Study